Akebia Therapeutics Inc
General ticker "AKBA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $409.7M
Akebia Therapeutics Inc follows the US Stock Market performance with the rate: 27.2%.
Estimated limits based on current volatility of 2.1%: low 1.80$, high 1.87$
Factors to consider:
- Company does not operate outside North America (retrieved using AI)
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.96$, 2.07$]
- 2024-12-30 to 2025-12-30 estimated range: [0.86$, 1.91$]
Financial Metrics affecting the AKBA estimates:
- Negative: Non-GAAP EPS, $ of -0.28 <= 0.10
- Negative: Operating profit margin, % of -19.20 <= 1.03
- Negative: Operating cash flow per share per price, % of -10.03 <= 2.35
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Inventory ratio change, % of 1.66 > 1.08
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term AKBA quotes
Long-term AKBA plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $211.65MM | $292.48MM | $194.62MM |
Operating Expenses | $476.15MM | $373.26MM | $240.88MM |
Operating Income | $-264.50MM | $-80.78MM | $-46.26MM |
Non-Operating Income | $-17.52MM | $-13.45MM | $-5.67MM |
Interest Expense | $19.94MM | $15.69MM | $6.03MM |
R&D Expense | $147.85MM | $129.11MM | $63.08MM |
Income(Loss) | $-282.02MM | $-94.23MM | $-51.92MM |
Profit(Loss) | $-282.02MM | $-94.23MM | $-51.92MM |
Stockholders Equity | $74.01MM | $5.23MM | $-30.58MM |
Inventory | $38.20MM | $21.76MM | $15.69MM |
Assets | $529.35MM | $356.05MM | $241.70MM |
Operating Cash Flow | $-252.97MM | $-73.15MM | $-23.38MM |
Capital expenditure | $0.06MM | $0.11MM | $0.00MM |
Investing Cash Flow | $39.94MM | $-0.11MM | $0.00MM |
Financing Cash Flow | $133.73MM | $14.60MM | $-25.21MM |
Earnings Per Share* | $-1.48 | $-0.58 | $-0.28 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.